Literature DB >> 31322990

Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer.

K M Islam1, Poppy E Deviany2, Trisari Anggondowati2, June E Ryan3, Ann Fetrick2, Danstan Bagenda4, Mehmet S Copur5, Addison Tolentino6,7, Irfan Vaziri8, Heidi A McKean6, Steven Dunder9, Jhanelle E Gray10, Chao M D Huang11, Apar Kishor Ganti4,12.   

Abstract

PURPOSE: In the United States, lung cancer accounts for 14% of cancer diagnoses and 28% of cancer deaths annually. Because no cure exists for advanced lung cancer, the primary treatment goal is to prolong survival.
OBJECTIVES: The study aim was to determine whether individual preferences, characteristics, and treatment experiences affect the meaning of treatment success.
MATERIALS AND METHODS: A quantitative study using an observational, longitudinal cohort of patients with advanced stage non-small-cell lung cancer was conducted. Data sources included medical records and patient interviews. Data were analyzed using χ2, Fisher's exact, and McNemar's tests, as well as logistic regressions.
RESULTS: At the first interview of 235 individuals, 12% considered survival alone as their definition of treatment success; others defined treatment success as survival plus other aspects, such as quality of life and reaching an important personal goal. As they moved through chemotherapy, 47% of the patients changed their definition of treatment success. Bivariate analysis showed that patients with lower incomes tended to be more likely to change their definition of treatment success compared with their counterparts with higher income (P = .0245).
CONCLUSION: By taking chemotherapy, patients expect to increase their odds of survival and want to maintain the quality of life and functionality. A patient's definition of treatment success is often changing as treatment continues, making it appropriate to ensure patient-provider communication throughout their clinical care. The study results are limited to patients with advanced non-small-cell lung cancer and drawn from a predominantly white patient population, mainly from the US Midwest.

Entities:  

Year:  2019        PMID: 31322990     DOI: 10.1200/JOP.18.00734

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  4 in total

1.  Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology.

Authors:  Mitchell S von Itzstein; Elda Railey; Mary L Smith; Carol B White; George W Sledge; John R Howell; Wendy Lawton; Donna M Marinucci; Nisha Unni; David E Gerber
Journal:  Cancer       Date:  2020-01-22       Impact factor: 6.860

2.  Understanding the lived experience of lung cancer: a European social media listening study.

Authors:  Ana Rodrigues; Jyoti Chauhan; Alexandros Sagkriotis; Sathyaraj Aasaithambi; Michele Montrone
Journal:  BMC Cancer       Date:  2022-04-30       Impact factor: 4.638

3.  A qualitative study of interactions with oncologists among patients with advanced lung cancer.

Authors:  Morhaf Al Achkar; Upal Basu Roy; Eugene Manley; Maisha Standifer; Christina Baik; Casey A Walsh
Journal:  Support Care Cancer       Date:  2022-08-11       Impact factor: 3.359

Review 4.  Stakeholder Perceptions of Key Aspects of High-Quality Cancer Care to Assess with Patient Reported Outcome Measures: A Systematic Review.

Authors:  Angela M Stover; Rachel Kurtzman; Jennifer Walker Bissram; Jennifer Jansen; Philip Carr; Thomas Atkinson; C Tyler Ellis; Ashley T Freeman; Kea Turner; Ethan M Basch
Journal:  Cancers (Basel)       Date:  2021-07-20       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.